Antifungal lock therapy

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 1-8

  Walraven, Carla J ^a,b   Lee, Samuel A ^a,b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CHITOSAN; CIPROFLOXACIN; CITRATE TRISODIUM; DOXYCYCLINE; ECHINOCANDIN; EDETATE SODIUM; EDETIC ACID; FLUCONAZOLE; HEPARIN; ITRACONAZOLE; LACTOFERRIN; MEROPENEM; MICAFUNGIN; MINOCYCLINE; POSACONAZOLE; RIFAMPICIN; TAUROLIDINE; TAUROLIDINE POLYVINYLPYROLIDINE; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ANTIFUNGAL LOCK THERAPY; ANTIFUNGAL RESISTANCE; BIOFILM; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CATHETER INFECTION; CATHETER REMOVAL; DRUG BINDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG PENETRATION; DRUG THERAPY; FUNGAL VIRULENCE; FUNGUS GROWTH; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUORUM SENSING; SCANNING ELECTRON MICROSCOPY; SHORT SURVEY; YARROWIA LIPOLYTICA;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; CLINICAL TRIALS AS TOPIC; ECHINOCANDINS; ETHANOL; HEPARIN; HUMANS; IRON CHELATING AGENTS;

EID: 84872012522     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01351-12     Document Type: Short Survey

References (78)

1. Segarra-Newnham M, Martin-Cooper EM. 2005. Antibiotic lock technique: a review of the literature. Ann. Pharmacother. 39:311-318. (Pubitemid 40165222)
2. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. 2009. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 49:1-45.
3. Dix CH, Yeung DT, Rule ML, Ma DD. 2011. Essential, but at what risk? A prospective study on central venous access in patients with haematological malignancies. Intern. Med. J. 42:901-906.
4. Peris A, Zagli G, Bonizzoli M, Cianchi G, Ciapetti M, Spina R, Anichini V, Lapi F, Batacchi S. 2010. Implantation of 3951 long-term central venous catheters: performances, risk analysis, and patient comfort after ultrasound-guidance introduction. Anesth. Analg. 111:1194-1201.
5. Chaftari AM, Kassis C, El Issa H, Al Wohoush I, Jiang Y, Rangaraj G, Caillouet B, Pravinkumar SE, Hachem RY, Raad II. 2011. Novel approach using antimicrobial catheters to improve the management of central line-associated bloodstream infections in cancer patients. Cancer 117: 2551-2558.
6. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
7. Korbila IP, Bliziotis IA, Lawrence KR, Falagas ME. 2007. Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current evidence. Expert Rev. Anti Infect. Ther. 5:639-652. (Pubitemid 47250136)
8. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. 2005. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J. Antimicrob. Chemother. 55:90-94. (Pubitemid 40192619)
9. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
10. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317. (Pubitemid 39050477)
11. Ramage G, Mowat E, Jones B, Williams C, López-Ribot J. 2009. Our current understanding of fungal biofilms. Crit. Rev. Microbiol. 35:340-355.
12. Kojic EM, Darouiche RO. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-267. (Pubitemid 38534029)
13. Tumbarello M, Posteraro B, Trecarichi EM, Fiori B, Rossi M, Porta R, de Gaetano Donati K, La Sorda M, Spanu T, Fadda G, Cauda R, Sanguinetti M. 2007. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol. 45:1843-1850. (Pubitemid 46933916)
14. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM. 1995. Microbial biofilms. Annu. Rev. Microbiol. 49:711-745.
15. Donlan RM. 2002. Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8:881-890. (Pubitemid 35000803)
16. Alem MA, Oteef MD, Flowers TH, Douglas LJ. 2006. Production of tyrosol by Candida albicans biofilms and its role in quorum sensing and biofilm development. Eukaryot. Cell 5:1770-1779. (Pubitemid 44622603)
17. Ramage G, Saville SP, Wickes BL, López-Ribot JL. 2002. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl. Environ. Microbiol. 68:5459-5463. (Pubitemid 35265681)
18. Ramage G, Wickes BL, López-Ribot JL. 2001. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am. Clin. Lab. 20:42-44.
19. LaFleur MD, Kumamoto CA, Lewis K. 2006. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother. 50:3839-3846. (Pubitemid 44684901)
20. Nett JE, Sanchez H, Cain MT, Andes DR. 2010. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J. Infect. Dis. 202:171-175.
21. Ramage G, Saville SP, Thomas DP, López-Ribot JL. 2005. Candida biofilms: an update. Eukaryot. Cell 4:633-638. (Pubitemid 40600417)
22. Lewis RE, Kontoyiannis DP, Darouiche RO, Raad II, Prince RA. 2002. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob. Agents Chemother. 46:3499-3505. (Pubitemid 35192917)
23. Ramage G, VandeWalle K, Bachmann SP, Wickes BL, López-Ribot JL. 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46:3634-3636. (Pubitemid 35192940)
24. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780. (Pubitemid 34535196)
25. Miceli MH, Bernardo SM, Lee SA. 2009. In vitro analysis of the occurrence of a paradoxical effect with different echinocandins and Candida albicans biofilms. Int. J. Antimicrob. Agents 34:500-502.
26. Ku TS, Bernardo SM, Lee SA. 2011. In vitro assessment of the antifungal and paradoxical activity of different echinocandins against Candida tropicalis biofilms. J. Med. Microbiol. 60:1708-1710.
27. Cateau E, Rodier MH, Imbert C. 2008. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J. Antimicrob. Chemother. 62:153-155. (Pubitemid 351865889)
28. Cateau E, Berjeaud JM, Imbert C. 2011. Possible role of azole and echinocandin lock solution in the control of Candida biofilms associated with silicone. Int. J. Antimicrob. Agents 37:380-384.
29. Oncu S. 2011. In vitro effectiveness of antifungal lock solutions on catheters infected with Candida species. J. Infect. Chemother. 17:634-639.
30. Raad I, Hachem RY, Hanna HA, Fang X, Jiang Y, Dvorak T, Sherertz RJ, Kontoyiannis DP. 2008. Role of ethylene diamine tetra-acetic acid (EDTA) in catheter lock solutions: EDTA enhances the antifungal activity of amphotericin B lipid complex against Candida embedded in biofilm. Int. J. Antimicrob. Agents 32:515-518.
31. Ko KS, Lee JY, Song JH, Peck KR. 2010. In vitro evaluation of antibiotic lock technique for the treatment of Candida albicans, C. glabrata, and C. tropicalis biofilms. J. Korean Med. Sci. 25:1722-1726.
32. Toulet D, Debarre C, Imbert C. 2012. Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials? J. Antimicrob. Chemother. 67:430-432.
33. Ramage G, Vande Walle K, Wickes BL, López-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479. (Pubitemid 32801898)
34. Chatzimoschou A, Katragkou A, Simitsopoulou M, Antachopoulos C, Georgiadou E, Walsh TJ, Roilides E. 2011. Activities of triazoleechinocandin combinations against Candida species in biofilms and as planktonic cells. Antimicrob. Agents Chemother. 55:1968-1974.
35. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, López-Ribot JL. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596. (Pubitemid 35192931)
36. Katragkou A, Chatzimoschou A, Simitsopoulou M, Dalakiouridou M, Diza-Mataftsi E, Tsantali C, Roilides E. 2008. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob. Agents Chemother. 52:357-360.
37. Shuford JA, Piper KE, Steckelberg JM, Patel R. 2007. In vitro biofilm characterization and activity of antifungal agents alone and against sessile and planktonic clinical Candida albicans isolates. Diagn. Microbiol. Infect. Dis. 57:277-281. (Pubitemid 46330658)
38. Tobudic S, Kratzer C, Lassnigg A, Graninger W, Presterl E. 2010. In vitro activity of antifungal combinations against Candida albicans biofilms. J. Antimicrob. Chemother. 65:271-274.
39. Miceli MH, Bernardo SM, Ku TS, Walraven C, Lee SA. 2012. In vitro analyses of the effects of heparin and parabens on Candida albicans biofilms and planktonic cells. Antimicrob. Agents Chemother. 56:148-153.
40. Ku TS, Palanisamy SKA, Lee SA. 2010. Susceptibility of Candida albicans biofilms to azithromycin, tigecycline, and vancomycin and the interaction between tigecycline and antifungals. Int. J. Antimicrob. Agents 36:441-446.
41. Miceli MH, Bernardo SM, Lee SA. 2009. In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int. J. Antimicrob. Agents 34:326-332.
42. Sherertz RJ, Boger MS, Collins CA, Mason L, Raad II. 2006. Comparative in vitro efficacies of various catheter lock solutions. Antimicrob. Agents Chemother. 50:1865-1868.
43. Raad I, Chatzinikolaou I, Chaiban G, Hanna H, Hachem R, Dvorak T, Cook G, Costerton W. 2003. In vitro and ex vivo activities of minocycline and EDTA against microorganisms embedded in biofilm on catheter surfaces. Antimicrob. Agents Chemother. 47:3580-3585. (Pubitemid 37345723)
44. Raad I, Hanna H, Dvorak T, Chaiban G, Hachem R. 2007. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob. Agents Chemother. 51:78-83. (Pubitemid 46047690)
45. Balestrino D, Souweine B, Charbonnel N, Lautrette A, Aumeran C, Traore O, Foestier C. 2009. Eradication of microorganisms embedded in biofilm by an ethanol-based catheter-lock solution. Nephrol. Dial. Transplant. 24:3204-3209.
46. Venkatesh M, Rong L, Raad I, Versalovi J. 2009. Novel synergistic antibiofilm combinations for salvage of infected catheters. J. Med. Microbiol. 58:936-944.
47. Percival SL, Kite P, Eastwood K, Murga R, Carr J, Arduino MJ, Donlan RM. 2005. Tetrasodium EDTA as a novel central venous catheter lock solution against biofilm. Infect. Control Hosp. Epidemiol. 26:515-519. (Pubitemid 40896140)
48. Martins M, Uppuluri P, Thomas DP, Cleary IA, Henriques M, Lopez- Ribot JL, Oliveira R. 2010. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia 169:323-331.
49. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. 2012. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 55:80-85.
50. Martinez LR, Mihu MR, Tar M, Cordero RJ, Han G, Friedman AJ, Friedman JM, Nosanchuk JD. 2010. Demonstration of antibiofilm and antifungal efficacy of chitosan against candidal biofilms, using an in vivo central venous catheter model. J. Infect. Dis. 201:1436-1440.
51. Shah CB, Mittelman MW, Costerton JW, Parenteau S, Pelak M, Arsenault R, Mermel LA. 2002. Antimicrobial activity of a novel catheter lock solution. Antimicrob. Agents Chemother. 46:1674-1679. (Pubitemid 34535182)
52. Alem MA, Douglas LJ. 2005. Prostaglandin production during growth of Candida albicans biofilms. J. Med. Microbiol. 54:1001-1005. (Pubitemid 41566768)
53. Rane HS, Bernardo SM, Walraven CJ, Lee SA. 2012. In vitro analyses of ethanol activity against Candida albicans biofilms. Antimicrob. Agents Chemother. 56:4487-4489.
54. Ghannoum MA, Isham N, Jacobs MR. 2011. Antimicrobial activity of B-Lock against bacterial and Candida spp. causing catheter-related bloodstream infections. Antimicrob. Agents Chemother. 55:4430-4431.
55. Beyda ND, Lewis RE, Garey KW. 2012. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches. Ann. Pharmacother. 46:1086-1096.
56. Canton E, Espinel-Ingroff A, Peman J, del Castillo L. 2010. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob. Agents Chemother. 54:2194-2197.
57. Harriott MM, Noverr MC. 2011. Importance of Candida-bacterial polymicrobial biofilms in disease. Trends Microbiol. 19:557-563.
58. Luzzaro F, Ortisi G, Larosa M, Drago M, Brigante G, Gesu G. 2011. Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagn. Microbiol. Infect. Dis. 69:363-369.
59. Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN. 2007. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn. Microbiol. Infect. Dis. 59:401-406. (Pubitemid 350184233)
60. Al-Fattani MA, Douglas LJ. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 55:999-1008. (Pubitemid 44215557)
61. Harriott MM, Noverr MC. 2009. Candida albicans and Staphylococcus aureus form polymicrobial biofilms: effects on antimicrobial resistance. Antimicrob. Agents Chemother. 53:3914-3922.
62. Peters BM, Jabra-Rizk MA, Scheper MA, Leid JG, Costerton JW, Shirtliff ME. 2010. Microbial interactions and differential protein expression in Staphylococcus aureus-Candida albicans dual-species biofilms. FEMS Immunol. Med. Microbiol. 59:493-503.
63. Peters BM, Ward RM, Rane HS, Lee SA, Noverr MC. 2012. Efficacy of ethanol against Candida albicans and Staphylococcus aureus polymicrobial biofilms. Antimicrob. Agents Chemother. 57:74-82.
64. Mukherjee PK, Long L, Kim HG, Ghannoum MA. 2009. Amphotericin B lipid complex is efficacious in the treatment of Candida albicans biofilms using a model of catheter-associated Candida biofilms. Int. J. Antimicrob. Agents 33:149-153.
65. Schinabeck MK, Long LA, Hossain MA, Chandra J, Mukherjee PK, Mohamed S, Ghannoum MA. 2004. Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy. Antimicrobial Agents Chemother. 48:1727-1732. (Pubitemid 38544381)
66. Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. 2006. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J. Infect. Dis. 194:710-713. (Pubitemid 44297859)
67. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. 2009. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J. Antimicrob. Chemother. 64:567-570.
68. Krzywda EA, Andris DA, Edmiston CE, Quebbeman EJ. 1995. Treatment of Hickman catheter sepsis using antibiotic lock technique. Infect. Control Hosp. Epidemiol. 16:596-598.
69. Özdemir H, Karbuz A, Ciftci E, Dincaslan HU, Ince E, Aysev D, Yuvuz G, Dogru U. 2011. Successful treatment of central venous catheter infection due to Candida lipolytica by caspofungin-lock therapy. Mycoses 54: e647-e649. doi:10.1111/j.1439-0507.2010.01964.x.
70. Blackwood RA, Klein KC, Micel LN, Willers ML, Mody RJ, Teitelbaum DH, Cober MP. 2011. Ethanol locks therapy for resolution of fungal catheter infections. Pediatr. Infect. Dis. J. 30:1105-1107.
71. Arnow PM, Kushner R. 1991. Malassezia furfur catheter infection cured with antibiotic lock therapy. Am. J. Med. 90:128-130.
72. Johnson DC, Johnson FL, Goldman S. 1994. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr. Infect. Dis. J. 13:930-931. (Pubitemid 24322793)
73. Benoit JL, Carandang G, Sitrin M, Arnow PM. 1995. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin. Infect. Dis. 21:1286-1288.
74. Viale P, Petrosillo N, Signorini L, Puoti M, Carosi G. 2001. Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections? Clin. Infect. Dis. 33:1947-1948. (Pubitemid 33105140)
75. Castagnola E, Marazzi MG, Tacchella A, Giacchino R. 2005. Broviac catheter-related candidemia. Pediatr. Infect. Dis. J. 24:747.
76. Angel-Moreno A, Boronat M, Bolanos M, Carrillo A, Gonzalez S, Perez Arellano JL. 2005. Candida glabrata fungemia cured by antibiotic lock therapy: case report and short review. J. Infect. 51:e85-e87. doi:10.1016/j.jinf.2004.08. 034. (Pubitemid 41554845)
77. Wu CY, Lee PI. 2007. Antibiotic-lock therapy and erythromycin for treatment of catheter-related Candida parapsilosis and Staphylococcus aureus infections. J. Antimicrob. Chemother. 60:706-707.
78. Buckler BS, Sams RN, Goei VL, Krishnan KR, Bemis MJ, Parker DP, Murray DL. 2008. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy. Pediatr. Infect. Dis. J. 27: 760-764.